ALBA Network
Exhibition, stand number 11

The ALBA Network, a division of FENS, was created to promote equity and diversity in the brain sciences. The goals of ALBA are to recognize implicit bias and discrimination, and to provide better visibility and professional development opportunities to scientists from underrepresented groups in brain research. This is achieved by highlighting diverse scientist profiles through a series of interviews; organizing webinars to discuss EDI issues, awards, mentoring sessions, and networking events; and providing a platform to disseminate data and best practices toward creating a more inclusive brain research community. To discover all our activities and become a member, visit www.alba.network.

Angelini Pharma
Industry Mini Session IMS05 — Invitation flyer

Angelini Pharma is an international pharmaceutical company, part of the Italian privately-owned Angelini Industries.
The company researches, develops and commercializes health solutions with a prevalent focus on the areas of Mental Health, Epilepsy and Consumer Healthcare, with highly successful self–medication drugs worldwide. Founded in Italy at the beginning of the 20th century, Angelini Pharma operates directly in 20 countries employing more than 3.000 people. Its products are marketed in over 70 countries even through strategic alliances with leading international pharmaceutical groups.
For additional information visit www.angelinipharma.com

Bristol Myers Squibb
Industry Satellite Symposium ISS05 — Invitation flyer

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
https://www.bmsmedical.com/

Boehringer Ingelheim
Industry Satellite Symposium ISS03 — Invitation flyer
Industry Satellite Symposium ISS04 — Invitation flyer
Exhibition, stand number 3

We’re a company who is committed to keeping minds connected. At Boehringer Ingelheim, we’re redefining healthcare to help people thrive. We’re pioneering holistic solutions that address the underlying symptoms that cut people off from what’s important in their own lives. And we’re partnering with advocates, researchers, and others in the mental health community to strengthen the connections that matter. Because every mind matters. Championing every mind for generations.
www.boehringer-ingelheim.com

concentris research management gmbh
Exhibition, stand number 14

concentris – Project management and marketing for your EU-funded research! We are specialised in PROPOSAL WRITING, PROJECT MANAGEMENT, DISSEMINATION / COMMUNICATION / TRAINING, and MEETING ORGANISATION for EU-funded “Horizon Europe” projects. We carry out all non-scientific tasks and provide support and consultancy for scientists from the first project idea to project completion. Our interdisciplinary team consists of project managers with scientific backgrounds, graphics designers, web developers, and social media experts with a passion for research.
https://www.concentris.de

Dr. Willmar Schwabe
Industry Mini Session IMS11 — Invitation flyer
Exhibition, stand number 9

Schwabe's main indication areas include cognitive decline, anxiety disorders, depression, and insomnia. The efficacy and safety of our plant-based medications has been demonstrated in dozens of randomized, placebo-controlled clinical trials, that were designed according to the highest clinical trial standards. Schwabe medication has been recommended in national and international medical guidelines. The company has been family-owned since it was founded in 1865 by the great-grandfather of the current CEO, Olaf Schwabe. In its 159-year history, it has remained committed to its tradition of being the driver of consistent innovation in safe and evidence-based natural treatments that your patients appreciate.
https://www.schwabe-group.com/en

Empatica
Exhibition, stand number 8

Empatica is a full-stack digital healthcare company and a pioneer in digital biomarker development and continuous health monitoring driven by AI. The FDA-cleared Empatica Health Monitoring Platform consists of the medical-grade EmbracePlus wearable, software, and digital measures, that can accurately and continuously monitor patient health remotely and unobtrusively, across a range of health conditions. Empatica’s solutions are currently being used by thousands of research partners, institutions, and patients, to run decentralized clinical trials, develop novel digital biomarkers, conduct academic research with real-world data, and monitor neurological conditions. Empatica’s Embrace wearable was the world’s first FDA-cleared smart watch in neurology to detect epileptic seizures. This year, Empatica launched its successor in the US, EpiMonitor, with all of the most loved features of Embrace and more.
https://www.empatica.com

EUFAMI
Exhibition, stand number 16

EUFAMI was founded in 1992 after a congress, which took place in 1990 in De Haan, Belgium, where carers from all over Europe shared their experiences of helplessness and frustration when living with severe mental illness. They resolved to work together to help both themselves and the people they cared for. EUFAMI is a democratic organisation, registered in Belgium as an international non-profit organisation. We have an ongoing commitment to improving care and welfare for people affected by mental illness. We also enable our member organisations to act jointly at a European Level, combining their efforts and sharing experience.
www.eufami.org

European Academy of Neurology (EAN)
Exhibition, stand number 12

The European Academy of Neurology (EAN) is a non-profit organisation representing more than 45,000 neurologists across 47 countries. With 31 Scientific and Coordinating Panels composed of experts on a range of neurological specialties, EAN is the home of neurology expertise in Europe. EAN’s mission is to reduce the burden of neurological diseases and to foster and support the development of neurological excellence in Europe and across the world, leading to better patient care and outcomes. EAN aims to promote quality in neurology and bring together Europe’s best clinicians, educators and scientists in the field to achieve their mission.
https://www.ean.org

European Brain Council (EBC)
Exhibition, stand number 15

The European Brain Council (EBC) is a network of key players in the “Brain Area”, with a membership encompassing scientific societies, patient organisations, professional societies and industry partners. A non-profit organisation based in Brussels, its main mission is to promote brain research with the ultimate goal of improving the lives of the estimated 179 million Europeans living with brain conditions. With the aim to speak with one voice, EBC stands as the platform to foster cooperation between its member organisations and other stakeholders, consistently promoting dialogue between scientists, industry and society.
www.braincouncil.eu

European Psychiatric Association (EPA)
Exhibition, stand number 10

With activities that address the interests of psychiatrists in academia, research and practice throughout all stages of career evolution, the European Psychiatric Association is the main association representing psychiatry in Europe. Being a part of the EPA means joining a community of practitioners, scientists, and professionals who are committed to the improvement of care for the mentally ill and to the development of professional excellence. With the help of mental health care partners across all related disciplines, the EPA’s leaders and members also strive to enact positive policy change at local, national and international levels.
www.europsy.net

GAMIAN-Europe
Exhibition, stand number 17

Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe), is a not-for-profit patient-driven pan-European organisation, representing and advocating the interests and rights of persons affected by mental ill health. Its principal activities relate to advocacy, information, awareness-raising, education, partnership and capacity building. Overarching themes in our work relate to anti-stigma and discrimination and patients’ rights.
www.gamian.eu

Gedeon Richter Plc and RECORDATI S.p.A
Industry Satellite Symposium ISS01 — Invitation flyer
Industry Mini Session IMS04 — Invitation flyer
Exhibition, stand number 5

Headquartered in Hungary, Gedeon Richter is an innovation-driven speciality pharmaceutical company, boasting the biggest pharmaceutical research centre in CEU. One of its latest achievements is the original antipsychotic compound, cariprazine, already marketed in the US for for Schizophrenia, BD and aMDD treatment and in the majority of the EU countries for the treatment of schizophrenia in adult patients.
www.gedeonrichter.com/

Recordati is an international pharmaceutical group, listed on the Italian Stock Exchange, dedicated to the research, development and marketing of pharmaceuticals products. Recordati is committed to the research and development of new specialities in cardiovascular, urological and psychiatric areas with a focus on treatments for rare diseases.
www.recordati.it

GH Research
Industry Mini Session IMS09 — Invitation flyer

GH Research is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The initial focus is on developing a novel and proprietary 5- Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapy for the treatment of patients with Treatment Resistant Depression. The lead product candidate, GH001, is formulated for 5-MeO-DMT administration via a proprietary inhalation approach.
www.ghres.com

H. Lundbeck A/S
Industry Mini Session IMS01 — Invitation flyer
Industry Mini Session IMS08 — Invitation flyer
Exhibition, stand number 4

Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options.

Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of.
www.lundbeck.com

Janssen Pharmaceutica NV
Industry Satellite Symposium ISS06 — Invitation flyer
Industry Mini Session: IMS03 — Invitation flyer
Industry Mini Session: IMS06 — Invitation flyer
Exhibition, stand number 2

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Follow us at https://www.linkedin.com/company/jnj-innovative-medicine-emea for our latest news.
www.janssen.com/emea

Maj Institute of Pharmacology PAS
Exhibition, stand number 13

Maj Institute of Pharmacology Polish Academy of Sciences in Kraków, founded in 1974 is currently one of the leading scientific units in Poland, specializing in neuro- and psychopharmacology. Scientific investigations, conducted in 14 departments, laboratories and modern animal house, focus on the nervous system disorders and the search for new biologically active substances that act on the central nervous system and can be used in the treatment of neurological and psychiatric conditions.
http://if-pan.krakow.pl/

Neuroscience based Nomenclature (NbN)
Exhibition, stand number 18

Our current, disease-based, nomenclature uses the terms "antidepressants", "antipsychotics" (including "second generation" antipsychotics), "mood stabilizers", "anxiolytics" etc., which does not do justice to the wealth of neuroscience knowledge that has been accumulated in the past 60 years. In order to address this issue, the ECNP initiated NbN - a product of an unprecedented, unique collaboration of five colleges of neuropsychopharmacology: ECNP, CINP, ACNP, AsCNP, and IUPHAR. The proposal was to move from a disease-based to a pharmacologically-driven nomenclature. By doing so, NbN enriches our vocabulary; using pharmacology in prescribing provides us with more than 60 groups of medications in our prescribing tool box.
www.NbN.science

Otsuka Pharmaceutical Europe Ltd.
Industry Satellite Symposium ISS02 — Invitation flyer

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Our 34,400 employees channel their passion and commitment into aiming to improve the health of our patients, with a focus in Europe on therapies in mental health, nephrology and immunology, haemato-oncology, infectious diseases and digital therapeutics.
www.otsuka-europe.com

Otsuka Pharmaceutical Europe Ltd and H. Lundbeck A/S
Industry Satellite Symposium ISS07 — Invitation flyer
Industry Mini Session IMS02 — Invitation flyer
Industry Product Theatre IPT01
Exhibition, stand number 1

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Our 34,400 employees channel their passion and commitment into aiming to improve the health of our patients, with a focus in Europe on therapies in mental health, nephrology, haemato-oncology, rare diseases, and digital therapeutics.
www.otsuka-europe.com

Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options.

Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of.
www.lundbeck.com

Takeda Pharmaceuticals International AG
Industry Interactive Discussion IID01 — Invitation flyer

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Teva Pharmaceuticals
Industry Mini Session IMS07 — Invitation flyer
Industry Mini Session IMS10 — Invitation flyer
Exhibition, stand number 6

Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,600 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products.
www.tevapharm.com

The Lundbeck Foundation
The Brain Prize, PL01

The Lundbeck Foundation is an enterprise foundation whose purpose is to create powerful ripple effects that bring discoveries to lives through investing actively in business and science at the frontiers of their fields.
The world’s largest brain research prize is awarded annually by the Lundbeck Foundation. Each year, they award 10 million DKK (approx. 1,3 million EUR) to one or more neuroscientists who have made a ground-breaking impact on brain research. The Brain Prize was first awarded in 2011 and has so far honoured 44 scientists from 11 different countries.
https://lundbeckfonden.com/en

Viatris
Industry Satellite Symposium ISS08 — Invitation flyer

Viatris is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world.
https://www.viatris.com/en

Wisepress Medical Bookshop
Exhibition, stand number 7

Wisepress.com is Europe’s leading conference bookseller. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on X (formerly known as Twitter) @WisepressBooks.
www.wisepress.com